Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics

M. Boesch, AG. Zeimet, D. Reimer, S. Schmidt, G. Gastl, W. Parson, F. Spoeck, J. Hatina, D. Wolf, S. Sopper,

. 2014 ; 5 (16) : 7027-39.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15023035

Cancer stem cells (CSC) are believed to be involved in tumor evasion of classical antitumor therapies and have thus become an attractive target for further improvement of anticancer strategies. However, the existence and identity of CSC are still a matter of controversy. In a systematic screen of 13 ovarian cancer cell lines we show that cells with stem cell properties are reliably detectable as a minor population, characterized by ABC transporter expression resulting in the side population (SP) phenotype. In different cell lines, either ABCG2 or ABCB1 was found to be responsible for this effect. Purified SP cells featured virtually all characteristics of bona fide CSC, including clonogenicity, asymmetric division and high tumorigenicity in vivo. Using in-depth phenotyping by multicolor flow cytometry, we found that among the investigated ovarian cancer cell lines the SP compartment exhibits tremendous heterogeneity and is composed of multiple phenotypically distinct subpopulations. Thus, our study confirms previous results showing that CSC are contained within the SP. However, the exact identity of the CSC is still disguised by the high complexity of the CSC-containing compartment. Further functional studies are needed to determine whether a single cellular subset can unambiguously be defined as CSC or whether multiple stem cell-like cells with different properties coexist. Moreover, the observed heterogeneity may reflect a high level of plasticity and likely influences tumor progression, escape from immune-surveillance and development of resistance to anticancer therapies and should therefore be considered in the development of new treatment strategies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15023035
003      
CZ-PrNML
005      
20150728092754.0
007      
ta
008      
150709s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.2053 $2 doi
035    __
$a (PubMed)25216521
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Boesch, Maximilian $u Internal Medicine V, Innsbruck Medical University, Innsbruck, Austria. Tyrolean Cancer Research Institute, Innsbruck, Austria.
245    14
$a The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics / $c M. Boesch, AG. Zeimet, D. Reimer, S. Schmidt, G. Gastl, W. Parson, F. Spoeck, J. Hatina, D. Wolf, S. Sopper,
520    9_
$a Cancer stem cells (CSC) are believed to be involved in tumor evasion of classical antitumor therapies and have thus become an attractive target for further improvement of anticancer strategies. However, the existence and identity of CSC are still a matter of controversy. In a systematic screen of 13 ovarian cancer cell lines we show that cells with stem cell properties are reliably detectable as a minor population, characterized by ABC transporter expression resulting in the side population (SP) phenotype. In different cell lines, either ABCG2 or ABCB1 was found to be responsible for this effect. Purified SP cells featured virtually all characteristics of bona fide CSC, including clonogenicity, asymmetric division and high tumorigenicity in vivo. Using in-depth phenotyping by multicolor flow cytometry, we found that among the investigated ovarian cancer cell lines the SP compartment exhibits tremendous heterogeneity and is composed of multiple phenotypically distinct subpopulations. Thus, our study confirms previous results showing that CSC are contained within the SP. However, the exact identity of the CSC is still disguised by the high complexity of the CSC-containing compartment. Further functional studies are needed to determine whether a single cellular subset can unambiguously be defined as CSC or whether multiple stem cell-like cells with different properties coexist. Moreover, the observed heterogeneity may reflect a high level of plasticity and likely influences tumor progression, escape from immune-surveillance and development of resistance to anticancer therapies and should therefore be considered in the development of new treatment strategies.
650    _2
$a zvířata $7 D000818
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a heterografty $7 D064593
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední NOD $7 D016688
650    _2
$a myši SCID $7 D016513
650    _2
$a nádorové kmenové buňky $x patologie $7 D014411
650    _2
$a nádory vaječníků $x patologie $7 D010051
650    _2
$a vedlejší populace buněk $x patologie $7 D058985
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Zeimet, Alain G $u Department of Gynecology and Obstetrics, Innsbruck Medical University, Innsbruck, Austria.
700    1_
$a Reimer, Daniel $u Department of Gynecology and Obstetrics, Innsbruck Medical University, Innsbruck, Austria.
700    1_
$a Schmidt, Stefan $u Internal Medicine V, Innsbruck Medical University, Innsbruck, Austria.
700    1_
$a Gastl, Guenther $u Internal Medicine V, Innsbruck Medical University, Innsbruck, Austria.
700    1_
$a Parson, Walther $u Institute of Legal Medicine, Innsbruck Medical University, Innsbruck, Austria.
700    1_
$a Spoeck, Franziska $u Internal Medicine V, Innsbruck Medical University, Innsbruck, Austria. Tyrolean Cancer Research Institute, Innsbruck, Austria.
700    1_
$a Hatina, Jiri $u Department of Biology and Biomedical Centre, Faculty of Medicine Pilsen, Charles University Prague, Pilsen, Czech Republic.
700    1_
$a Wolf, Dominik $u Internal Medicine V, Innsbruck Medical University, Innsbruck, Austria. Medical Clinic III, Oncology, Hematology and Rheumatology, University Clinic Bonn (UKB), Bonn, Germany. These authors contributed equally to this work.
700    1_
$a Sopper, Sieghart $u Internal Medicine V, Innsbruck Medical University, Innsbruck, Austria. Tyrolean Cancer Research Institute, Innsbruck, Austria. These authors contributed equally to this work.
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 5, č. 16 (2014), s. 7027-39
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25216521 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20150728092839 $b ABA008
999    __
$a ok $b bmc $g 1083374 $s 906028
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 5 $c 16 $d 7027-39 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
LZP    __
$a Pubmed-20150709

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace